Seminars in Oncology
Volume 33, Supplement 12 , Pages 18-24, December 2006

New and Emerging Intraperitoneal (IP) Drugs for Ovarian Cancer Treatment

  • Franco M. Muggia

      Affiliations

    • Dr. Muggia has received grant or research support from and serves on the speakers bureau for Ortho Biotech Products, L.P. He is also a member of the Bristol-Myers Squibb Company advisory committee.
    • Corresponding Author InformationAddress reprint requests to Franco M. Muggia, MD, New York University Cancer Institute, 462 First Avenue C & D, Building 226, New York, NY 10016-9196.

Division of Medical Oncology, New York University Medical Center, New York, NY.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc., a subsidiary of MedImmune, Inc.

PII: S0093-7754(06)00428-3

doi:10.1053/j.seminoncol.2006.11.006

Seminars in Oncology
Volume 33, Supplement 12 , Pages 18-24, December 2006

Article Tools